Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented strong financial performance with a 104% revenue increase YoY and improved gross margins. Despite a net loss, the reduction is notable. The Q&A highlighted a strong sales pipeline and positive reimbursement rates from private payers. While guidance was conservative, the company's bullish outlook and solid pipeline suggest potential growth. The market's response may be positive, especially with the anticipation of guideline recognition and commercial payer coverage. However, challenges in MR system integration and competitive pressures should be monitored. Overall, the sentiment leans towards a positive stock price movement.
Key Financial Performance
Revenue $5.3 million in Q1 2026, up 104% year-over-year from $2.6 million in Q1 2025. The increase was driven by $2.5 million from recurring revenue and $2.9 million from one-time sales of capital equipment.
Gross Margin 72% in Q1 2026, compared to 71% in Q1 2025. The increase was primarily due to a product mix with more capital equipment sold, which has a higher margin.
Operating Expenses $11.8 million in Q1 2026, down 9% year-over-year from $13 million in Q1 2025. The decrease was not attributed to specific reasons in the transcript.
Net Loss $7 million or $0.19 per share in Q1 2026, compared to $10.7 million or $0.36 per share in Q1 2025. The reduction in net loss reflects improved revenue and gross margin.
Cash $50.3 million as of March 31, 2026. No year-over-year comparison or reasons for change were provided.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
TULSA technology: The CAPTAIN trial demonstrated TULSA's superior quality of life outcomes compared to radical prostatectomy, achieving primary safety endpoints and better perioperative outcomes. TULSA is versatile, customizable, and supported by over 70 peer-reviewed publications and 200 scientific presentations. It is positioned as a new platform for prostate disease management.
Interventional MRI integration: TULSA is compatible with 4,000 MRs in the U.S., and interventional MRs like Siemens Free series are becoming commercially available. FDA clearance for integration with interventional MR is expected by year-end, potentially contributing to growth in 2027.
Market adoption of TULSA: TULSA is transitioning from early adopters to the mainstream market, establishing itself as a third distinct category in prostate disease treatment. The company aims to achieve 200 TULSA sites performing 50 cases per year to reach profitability.
Revenue growth: Q1 2026 revenue was $5.3 million, up 104% from Q1 2025. Full-year 2026 revenue is projected at $25 million, representing 56% growth compared to 2025.
Gross margin improvement: Q1 2026 gross margin was 72%, up from 71% in Q1 2025, driven by a favorable product mix. Full-year 2026 gross margin is expected to be 70% or higher.
Cost management: Operating expenses in Q1 2026 were $11.8 million, down 9% from Q1 2025. The company recorded a net loss of $7 million, an improvement from a $10.7 million loss in Q1 2025.
Growth strategy: The company is focused on demonstrating TULSA's flexibility and capability, publishing data on patient variety and same-store sales growth. It is also leveraging partnerships with MR companies to expand adoption.
Future growth drivers: Integration with interventional MR and achieving 200 TULSA sites are key to future growth. The company is targeting profitability through increased adoption and operational efficiencies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Performance: The company reported a net loss of $7 million in Q1 2026, despite revenue growth. This indicates ongoing financial challenges in achieving profitability.
Cash Burn: Although the company expects cash burn to decline, it remains a concern until revenue growth and profitability are achieved.
Market Adoption: The company is not yet at the 10% market penetration needed for an inflection point in adoption of its TULSA technology, which could delay broader market acceptance.
Regulatory Hurdles: FDA clearance for integration with new interventional MR systems is anticipated by year-end, but any delays could impact growth projections for 2027.
Operational Challenges: The need for compatible MR systems and collaboration between urology and radiology departments has been a significant hurdle in TULSA's commercialization.
Competitive Pressures: The prostate disease treatment space is highly competitive, with many alternative technologies vying to replace current standards of care.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: The company is projecting total revenue for full year 2026 to be approximately $25 million, representing 56% growth compared to last year.
Gross Margin Expectations: Profound Medical expects full year 2026 gross margin to be 70% or higher.
Profitability Path: The company believes it is on a path to profitable growth, with expectations of declining cash burn and eventual cash flow positivity as revenue grows and margins remain high.
TULSA Technology Growth: Profound Medical anticipates achieving 200 TULSA sites performing an average of at least 50 cases per year to reach profitability. The company is also projecting FDA clearance for integration with new interventional MR by year-end 2026, which is expected to contribute meaningfully to growth in 2027.
Market Expansion: The company is transitioning TULSA from early adopters to the mainstream market, establishing it as a third distinct category in prostate disease treatment.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you share any details about Humana's decision to begin coverage and the progression of other commercial payers?
A:The decision by Humana was influenced by a combination of over 70 publications and discussions with medical directors about where TULSA-PRO fits in the continuum of care for prostate disease. The rate for private insurers is approximately 1.5x to 2.5x Medicare rates. Other commercial payers are being engaged on a case-by-case basis, with an 80% success rate in reversing rejected cases.
Q:Are the 6 shipped but not installed systems expected to hit revenue in the current quarter?
A:The company recognizes revenue upon shipment of systems. Out of the 8 systems sold, 2 were installed, increasing the installed base to 80, while 6 were shipped but not yet installed. These systems will not treat patients immediately, which is why the distinction was made.
Q:What informed the company's guidance, and why does it seem conservative relative to Street expectations?
A:The guidance reflects a disciplined approach and serves as a starting point. The company remains bullish on its business and pipeline but aims to provide quantifiable and disciplined guidance. Adjustments to the guidance may be made as the business progresses.
Q:What is the status of the sales pipeline?
A:The pipeline remains strong, with accounts in the verify, negotiate, and contracting stages exceeding triple digits. These accounts share attributes with the company's Index 20, which reflects the future installed base.
Q:Can you describe the range of annualized procedures in the Index 20 and plans for maintaining or rebalancing it?
A:The Index 20 was designed to reflect the future installed base, including a mix of hospital types. The company will provide rolling 5-quarter data to show trends and plans to expand the index over time to include more sites.
Q:Is the capital sale model still the preferred approach, and how are customers responding?
A:Yes, the capital sale model is preferred and aligns with industry standards. Out of the 8 systems sold in Q1, only one was on a placement model. The model is well-received by hospital administrators and CFOs.
Q:Does the $25 million revenue guidance align with the target of 120 installations by the end of 2026?
A:Yes, the target of 120 installations by the end of 2026 remains unchanged. The $25 million revenue guidance is a starting point and does not reflect any changes in the company's pipeline or potential.
Q:Are you satisfied with the reimbursement rates from private payers compared to Medicare?
A:Yes, the reimbursement rates from private payers range from 1.5x to 2.5x Medicare rates, which is in line with or better than industry benchmarks. The company is optimistic about more private payers following Humana's lead.
Q:What is the progress on being included in AUA or other society guidelines?
A:The TULSA procedure is already named in the NCCN guidelines, which is a positive step. The company expects further recognition in guidelines like AUA and EU as more data is published and evidence accumulates.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the range of annualized procedures in the Index 20 and used vague language like 'things are cloudy' when discussing transparency and trends. Additionally, while they expressed optimism about guideline inclusion and private payer adoption, they did not provide concrete timelines or commitments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BPH care
CAPTAIN pillar
CAPTAIN rigor
CAPTAIN top
Dr Profound
Dr conference
IR calendar
Instructions Thursday
Level CAPTAIN
President Chief
TACT outcome
Thursday conference
activity employment
addition patient
afternoon lady
afternoon week
associated conference
calendar website
cancer information
care registry
case investigator
combination cancer
complication return
conference Investor
conference outcome
conference replay
continence function
debate treatment
effect TACT
efficacy debate
efficacy procedure
employment outcome
endpoint
evidence
gland treatment
outcome CAPTAIN
platform
quality life
safety
PROF Transcript
Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call presented strong financial performance with a 104% revenue increase YoY and improved gross margins. Despite a net loss, the reduction is notable. The Q&A highlighted a strong sales pipeline and positive reimbursement rates from private payers. While guidance was conservative, the company's bullish outlook and solid pipeline suggest potential growth. The market's response may be positive, especially with the anticipation of guideline recognition and commercial payer coverage. However, challenges in MR system integration and competitive pressures should be monitored. Overall, the sentiment leans towards a positive stock price movement.
Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.
Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Positive8-14
The earnings call highlights strong financial performance with improved gross margins and revenue growth. The CAPTAIN trial data and positive feedback from physicians enhance confidence in TULSA's efficacy. Although there are increased operating expenses and net losses, management's optimistic guidance, strategic partnerships, and successful marketing initiatives signal potential for growth. The Q&A session confirms positive sentiment, with plans for reduced cash burn and strategic expansions. The absence of negative guidance, coupled with favorable reimbursement scenarios, supports a positive outlook for the stock price over the next two weeks.
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Unknown5-9
The earnings call presents a mixed picture: strong revenue growth and promising product development (TULSA AI and CAPTAIN trial) are offset by increased net losses and operating expenses. The Q&A section reveals positive feedback on CAPTAIN data and insurer engagement, but management's vague responses on deal closures and financial guidance introduce uncertainty. The lack of shareholder return initiatives further tempers optimism. Despite potential for future growth, current financial instability and competitive pressures suggest a neutral stock price movement in the short term.
PROF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
